Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness of domestic paliperidone palmitate (Xingpida) in adult schizophrenia and impact on family burden
ChiCTR2600117300Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Jan 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by The First Hospital of Hebei Medical University. Primary endpoint: Schizophrenia efficacy at week 25. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2600117300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117300.